Church & Dwight grew faster than its categories across all three divisions in 2025, delivering 1% consumption growth on the reshaped portfolio and an adjusted 3.5% growth rate when excluding exits. Hero and TheraBreath achieved double-digit expansion, while weighted-average private-label exposure fell from roughly 12% to about 5%. The company acquired Touchland, divested the Spinbrush and VMS businesses, and closed Flawless and shower head operations. Management highlighted a balance-sheet leverage ratio near 1.5x, underpinning its capacity for further acquisitions.

In the fourth quarter, total sales rose 3.9%, driven principally by the Touchland acquisition, with organic sales up 0.7%—or 1.8% excluding the divested vitamin business. Gross margin expanded by 90 basis points year-over-year, reversing first-half pressure and setting a positive trajectory into 2026. EPS of $0.86 represented a 12% increase versus the prior year and exceeded company targets. For full-year 2025, revenue totaled $6.2 billion, organic growth stood at 0.7% (2% on a pro forma basis), and cash from operations reached $1.2 billion. The company returned $900 million to shareholders while maintaining a stable debt-to-EBITDA ratio.

Church & Dwight identified $190 million of tariff exposure in 2025 and reduced it to $25 million, leveraging rapid fact-gathering and execution. For 2026, management projects organic sales growth of 3% to 4% (with reported sales down 0.5% to 1.5% due to business exits), gross margin improvement of about 100 basis points, marketing investment at approximately 11% of sales, EPS growth of 5% to 8%, and cash from operations near $1.15 billion. The outlook assumes 2% category growth and emphasizes volume rather than price. The board approved a 4.2% dividend increase, marking the 125th year of payments and 30th consecutive annual hike.

Leadership outlined three strategic priorities: scale Arm & Hammer from $2 billion to $3 billion, grow TheraBreath from $1 billion to $1.5 billion, and expand international revenue from about $1 billion to $2 billion. In 2025, Arm & Hammer detergent share reached a record 14.5%, up 20 basis points, and cat litter share rose by roughly 20 basis points. TheraBreath became the second-largest mouthwash brand with nearly 22% share. Hero delivered three-times category growth and secured a 19% share in acne treatments. Internationally, revenue of $1.01 billion grew organically by 5.5%, with six of seven power brands gaining share across more than 75 countries.